CD274 and neoplasm: Both metabolites significantly promoted the anti-PD-L1 efficacy against PC <i>in situ</i> on a TRAMP mouse model.<h4>Conclusions</h4>Targeting the "gut-tumor metabolic axis" is a promising strategy to improve the efficacy of immune checkpoint inhibitors in tumors.